Reparixin is a noncompetitive allosteric inhibitor of IL-8 (CXCL8) activation of CXCR1 and CXCR2 chemokine receptors with IC50 of 1 and 100 nM, respectively. Reparixin effectively decreased systolic blood pressure and increased the blood flow. Treatment with reparixin significantly counteracts secondary degeneration by reducing oligodendrocyte apoptosis, migration to the injury site of neutrophils and ED-1-positive cells.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO: ≥ 25 mg/mL|
Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats.
Kim HY, et al. Biol Pharm Bull. 2011;34(1):120-7. PMID: 21212529.
Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
Moriconi A, et al. J Med Chem. 2007 Aug 23;50(17):3984-4002. PMID: 17665889.
|Related CXCR Products|
MSX-130 is CXCR4 Antagonist.
MSX-127 (NSC-23026) is a CXCR4 receptor modulator.
AZD-5069 is a potent CXCR2 chemokine receptor antagonist, and is claimed to be useful in the treatment of inflammatory diseases.
AMG 487 is a potent and selective antagonist of chemokine (C-X-C motif) receptor 3 (CXCR3) with IC50 values of 8nM and 8.2nM for I-IP-10 and I-ITAC, respectively.
SRT3109 is a CXCR2 ligand for use in the treatment of chemokine mediated diseases and conditions.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.